Take a new two-drug HIV medication combination or continue your current regimen

Recruiting

What is this trial?

This trial is testing a new two-drug HIV medication combination called doravirine/raltegravir in people whose HIV is already well-controlled and undetectable. Researchers want to see if this simpler combination can keep the virus undetectable while potentially reducing side effects that can build up over many years of HIV treatment. Half of participants will switch to the new medication immediately, while the other half will continue their current treatment for one year before switching.

People taking HIV medications long-term often experience side effects like heart disease, bone loss, kidney problems, and high cholesterol from their current drugs. This trial is exploring whether a simpler two-drug treatment might work just as well while causing fewer of these long-term health problems.

Do you qualify?

You likely qualify if…

you are at least 18 years old
you have been diagnosed with HIV-1
your CD4 count is 200 or higher
you have been on a stable HIV medication regimen for at least 6 months
your HIV viral load has been undetectable (50 copies/mL or lower) for at least the past year
you have never taken doravirine before and have no known resistance to doravirine or raltegravir

You likely don't qualify if…

you have untreated hepatitis B co-infection
you have severely low hemoglobin or platelet counts
your kidney function is significantly reduced (creatinine clearance below 60)
you have severe liver problems or are currently taking other medications that could interact with the new treatment
you are pregnant, breastfeeding, or unable to follow the trial protocol

What participation looks like

You will be randomly assigned to one of two groups: one group will immediately switch to the new two-drug combination, while the other group will continue their current HIV medications for 48 weeks and then switch. Throughout the trial, you'll have regular clinic visits to monitor your viral load, CD4 count, and overall health. The trial will track whether the new medication keeps your HIV undetectable and assess any side effects or changes in your health markers over time.

Testing a simpler two-drug combination for people with controlled HIV

What is this trial?

Do you qualify?

What participation looks like

Trial locations(1 site)